A jury has found that a vitamin C manufacturer based in China, as well as its affiliate company, are guilty of price-fixing in the US and have been ordered to pay $162 million. The $54.1 million in damages to the victims of the class action suit were trebled for Hebei Welcome Pharmaceutical Co Ltc, the vitamin C manufacturer. Sources say that the two defendants who were previously part of the case settled out of court for a reported $22.5 million. As CPI previously reported, the defendants had used a rare defense claiming that their company forced them to fix prices abroad, a defense known as the foreign sovereign compulsion doctrine.
Featured News
Obama Calls on Democrats to Confront Risks From Rapid AI Growth
Sep 13, 2026 by
CPI
Cravath Lands Six Weil Partners in High-Profile M&A Team Hire
Sep 13, 2026 by
CPI
Paramount, State AGs Set October Settlement Talks in Antitrust Fight
Sep 13, 2026 by
CPI
Broadcom’s VMware Licensing Changes Draw Deeper EU Antitrust Scrutiny
Sep 13, 2026 by
CPI
South Korea’s Antitrust Fines Hit Record as Regulator Steps Up Chaebol Scrutiny
Sep 13, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – State Attorneys General
Aug 27, 2026 by
CPI
CPI Talks… with Jonathan Skrmetti, Attorney General of Tennessee
Aug 27, 2026 by
Jonathan Skrmetti
What the Live Nation Jury Instructions Tell Us About California’s Unfair Competition Law
Aug 27, 2026 by
Henry Hauser, Brent Nakamura, Ashley Kaplan, Brian Wang & Cari Jeffries
From Backroom Deals to Public Scrutiny: The Tunney Act’s Past, Present, and Future
Aug 27, 2026 by
Christina M. Black & Ashley A. Locke
Understanding the Fragility of Economic Concentration Through the Principles of Ecology
Aug 27, 2026 by
Alexandra Spring